• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

ChemoMetec

409.60 DKK+2.91 %9.7. klo 17.59
Less than 1K followers

CHEMM

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+2.91 %
+8.88 %
+33.94 %
-42.91 %
-40.42 %
-25.53 %
-6.18 %
-54.03 %
+1,761.82 %

ChemoMetec specializes in the design, development, and production of patented instruments for cell counting and cell analysis. The company cooperates and statutes agreements with actors such as research institutes, universities, food companies, hospitals, and specialist clinics. Customers are found in a global market. The company was founded in 1997 and is headquartered in Alleröd, Denmark.

Read more
Market cap
7.13B DKK
Turnover
15.33M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
10.9.
2026

Annual report '26

8.10.
2026

General meeting '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release15.05.2026 klo 12.43

Initiation of buy-back programme

ChemoMetec
Regulatory press release06.05.2026 klo 19.52

Growth in revenue and operating profit

ChemoMetec
Regulatory press release04.05.2026 klo 16.17

Adjustment of accounting estimates contributes to an upgrade of revenue and operating profit guidance

ChemoMetec

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release27.03.2026 klo 11.06

Notification of managers’ transactions

ChemoMetec
Regulatory press release27.03.2026 klo 10.53

Notification of managers’ transactions

ChemoMetec
Regulatory press release26.03.2026 klo 12.40

Notification of managers’ transactions

ChemoMetec
Regulatory press release24.03.2026 klo 17.08

Adjustment of guidance for 2025/26

ChemoMetec
Regulatory press release02.03.2026 klo 11.50

Notification of managers’ transactions

ChemoMetec
Regulatory press release09.02.2026 klo 11.28

Notification of managers’ transactions

ChemoMetec
Regulatory press release04.02.2026 klo 19.16

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec
Regulatory press release04.02.2026 klo 19.09

Interim report 2025/26 - Organic growth despite challenges in the North American market

ChemoMetec
Regulatory press release07.11.2025 klo 14.27

Notification of managers’ transactions

ChemoMetec
Regulatory press release07.11.2025 klo 14.18

Notification of managers’ transactions

ChemoMetec
Regulatory press release06.11.2025 klo 18.11

Growth in revenue and operating profit

ChemoMetec
Regulatory press release28.10.2025 klo 12.06

Upgrade of guidance

ChemoMetec
Regulatory press release09.10.2025 klo 23.01

Procedure of the Annual General Meeting

ChemoMetec
Regulatory press release17.09.2025 klo 16.43

Notice of Annual General Meeting 2025

ChemoMetec
Regulatory press release11.09.2025 klo 20.16

Annual Report 2024/25 - Growing revenue and EBITDA

ChemoMetec
Regulatory press release11.09.2025 klo 20.12

Guidance for the 2025/26 financial year

ChemoMetec
Regulatory press release01.07.2025 klo 13.45

Preliminary revenue figures for the 2024/25 financial year

ChemoMetec